宫颈腺癌p53、HPV16/18-E6蛋白和ER的表达及其临床意义

目的　探讨宫颈腺癌组织中 p5 3蛋白、HPV16 / 18 E6蛋白及ER的表达及其临床意义。 方法　采用免疫组织化学S P法对 6 3例宫颈腺癌组织进行p5 3蛋白、HPV16 / 18 E6蛋白及ER检测。结果　 6 3例宫颈腺癌中p5 3、HPV16 / 18 E6蛋白和ER阳性表达率分别为为 5 2 .3%、31.7%和 4 9.2 %。p5 3表达与肿瘤病理分级、临床分期 (Ⅰ、Ⅱ、Ⅲ期 )有关。HPV16 / 18 E6、ER的表达与宫颈腺癌的病理学分级、临床分期无关 ,但与 p5 3表达呈负相关 (P <0 .0 1) ,HPV16 / 18 E6、ER在宫颈腺癌中的表达呈正相关 (P <0 .0 1)。结论　随宫颈腺癌组织病理分级和临床分期增高p5 3阳性表达率逐渐增高 ,可能与 p5 3突变有关 ,部分宫颈腺癌的发病可能与HPV16 / 18 E6蛋白过度表达有关。部分宫颈腺癌可能属于激素依赖性 ,雌激素可能有协同HPV致癌的作用。

Expression of p53, HPV16/18-E6 and ER and its clinical significance in uterine cervical adenocarcinoma

ObjectiveTo study the expression of p53, HPV16 /18-E6 and ER and its clinical significance in uterine cervical adenocarcinoma. MethodsThe expression of p53, HPV16 /18-E6 and ER was detected by immunohistochemical S-P method in 63 cases of cervical adenocarcinoma. ResultsPositive expression rates for p53 , HPV16 /18-E6 and ER in cervical adenocarcinoma were 52.3% (33 /63) , 31.7% (20 /63) and 49.2% (31 /63) respectively. Expression of p53 was positively relelated to pathological grades and clinical stages (P<0.05 and P<0.01 respectivly) . Expressions of HPV16 /18-E6 and ER were not related to the tumor grades and clinical stages (P>0.05). There was an apparent correlation between the expressions of HPV16 /18-E6 and ER(P<0.05). ConclusionThe over expression of HPV16 /18-E6 may play an important role in the pathogenesis of cervical adenocarcinoma. This result indicates that some of the cervical adenocarcinomas are estrogen dependent, and the estrogen may participate in the onset and progression of the tumor.